Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) have earned a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $26.50.
Several analysts have weighed in on ALPN shares. HC Wainwright boosted their price target on Alpine Immune Sciences from $17.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Morgan Stanley raised their target price on Alpine Immune Sciences from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, November 3rd. Berenberg Bank began coverage on Alpine Immune Sciences in a report on Tuesday, October 17th. They set a “buy” rating and a $18.00 target price on the stock. Royal Bank of Canada raised their target price on Alpine Immune Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. Finally, Wedbush raised their target price on Alpine Immune Sciences from $26.00 to $35.00 and gave the stock an “outperform” rating in a report on Friday, January 26th.
Insider Buying and Selling at Alpine Immune Sciences
Institutional Investors Weigh In On Alpine Immune Sciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Decheng Capital LLC acquired a new position in Alpine Immune Sciences during the 4th quarter worth $135,007,000. Decheng Capital Management III Cayman LLC purchased a new stake in shares of Alpine Immune Sciences in the 3rd quarter valued at about $76,810,000. BlackRock Inc. increased its position in Alpine Immune Sciences by 46.9% in the 2nd quarter. BlackRock Inc. now owns 2,281,692 shares of the biotechnology company’s stock valued at $23,456,000 after acquiring an additional 728,772 shares during the period. Vanguard Group Inc. increased its position in Alpine Immune Sciences by 5.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company’s stock valued at $16,887,000 after acquiring an additional 70,912 shares during the period. Finally, Franklin Resources Inc. acquired a new position in Alpine Immune Sciences during the 4th quarter worth approximately $23,260,000. Institutional investors and hedge funds own 75.17% of the company’s stock.
Alpine Immune Sciences Price Performance
Shares of ALPN stock opened at $30.38 on Tuesday. Alpine Immune Sciences has a 1-year low of $6.39 and a 1-year high of $30.65. The stock’s fifty day moving average price is $21.01 and its 200 day moving average price is $15.45. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -25.32 and a beta of 1.07.
Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.11. Alpine Immune Sciences had a negative return on equity of 33.53% and a negative net margin of 185.10%. The firm had revenue of $10.04 million for the quarter, compared to the consensus estimate of $8.73 million. As a group, equities research analysts anticipate that Alpine Immune Sciences will post -1.14 earnings per share for the current year.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.
- Five stocks we like better than Alpine Immune Sciences
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 attractive stocks that insiders are buying
- What is a Dividend King?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Toy Stocks
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.